| Variable . | CD with CKD (n = 87) . | CD without CKD (n = 148) . |
|---|---|---|
| Gender | ||
| Male | 49 (56.3) | 80 (54.1) |
| Female | 38 (43.7) | 68 (45.9) |
| Race | ||
| White | 79 (90.8) | 136 (91.9) |
| Black | 8 (9.2) | 12 (8.1) |
| Ethnicity | ||
| Hispanic | 26 (29.9) | 40 (27.0) |
| Non-Hispanic | 61 (70.1) | 108 (73.) |
| Age, mean (IQR) | 67 (18-91) | 66 (20-88) |
| Smoking status | ||
| Never smoker | 45 (51.7) | 79 (53.4) |
| Former smoker | 36 (41.4) | 57 (38.5) |
| Current smoker | 6 (6.9) | 12 (8.1) |
| Hypertension | 41 (47.1) | 40 (27.0) |
| Diabetes mellitus | 14 (16.1) | 15 (10.1) |
| Primary sclerosing cholangitis | 3 (3.4) | 2 (1.4) |
| End-stage renal disease | 13 (14.9) | 0 |
| History of kidney stones | 30 (34.5) | 8 (5.4) |
| History of transplant | 8 (9.2) | 0 |
| Kidney | 3 (3.4) | 0 |
| Liver | 4 (4.6) | 0 |
| Bowel | 1 (1.1) | 0 |
| Aminosalicylate use | ||
| Previous | 48 (55.2) | 105 (70.9) |
| Immunomodulator use | ||
| Current | 15 (17.2) | 39 (26.4) |
| Previous | 56 (64.4) | 79 (53.4) |
| Biologics use | ||
| Current | 47 (54.0) | 85 (57.4) |
| Previous | 61 (70.1) | 107 (72.3) |
| # of biologics used | ||
| 0 | 26 (29.9) | 41 (27.7) |
| 1 | 29 (33.3) | 56 (39.9) |
| 2 | 14 (16.1) | 25 (16.9) |
| 3+ | 18 (20.7) | 26 (17.5) |
| Steroid use | ||
| Previous | 80 (92.0) | 129 (87.2) |
| History of IBD-related surgery | 67 (77.0) | 74 (50.0) |
| # of IBD-related surgeries | ||
| 1 | 19 (21.8) | 43 (29.1) |
| 2 | 17 (19.5) | 20 (13.5) |
| 3+ | 31 (35.6) | 11 (7.4) |
| Variable . | CD with CKD (n = 87) . | CD without CKD (n = 148) . |
|---|---|---|
| Gender | ||
| Male | 49 (56.3) | 80 (54.1) |
| Female | 38 (43.7) | 68 (45.9) |
| Race | ||
| White | 79 (90.8) | 136 (91.9) |
| Black | 8 (9.2) | 12 (8.1) |
| Ethnicity | ||
| Hispanic | 26 (29.9) | 40 (27.0) |
| Non-Hispanic | 61 (70.1) | 108 (73.) |
| Age, mean (IQR) | 67 (18-91) | 66 (20-88) |
| Smoking status | ||
| Never smoker | 45 (51.7) | 79 (53.4) |
| Former smoker | 36 (41.4) | 57 (38.5) |
| Current smoker | 6 (6.9) | 12 (8.1) |
| Hypertension | 41 (47.1) | 40 (27.0) |
| Diabetes mellitus | 14 (16.1) | 15 (10.1) |
| Primary sclerosing cholangitis | 3 (3.4) | 2 (1.4) |
| End-stage renal disease | 13 (14.9) | 0 |
| History of kidney stones | 30 (34.5) | 8 (5.4) |
| History of transplant | 8 (9.2) | 0 |
| Kidney | 3 (3.4) | 0 |
| Liver | 4 (4.6) | 0 |
| Bowel | 1 (1.1) | 0 |
| Aminosalicylate use | ||
| Previous | 48 (55.2) | 105 (70.9) |
| Immunomodulator use | ||
| Current | 15 (17.2) | 39 (26.4) |
| Previous | 56 (64.4) | 79 (53.4) |
| Biologics use | ||
| Current | 47 (54.0) | 85 (57.4) |
| Previous | 61 (70.1) | 107 (72.3) |
| # of biologics used | ||
| 0 | 26 (29.9) | 41 (27.7) |
| 1 | 29 (33.3) | 56 (39.9) |
| 2 | 14 (16.1) | 25 (16.9) |
| 3+ | 18 (20.7) | 26 (17.5) |
| Steroid use | ||
| Previous | 80 (92.0) | 129 (87.2) |
| History of IBD-related surgery | 67 (77.0) | 74 (50.0) |
| # of IBD-related surgeries | ||
| 1 | 19 (21.8) | 43 (29.1) |
| 2 | 17 (19.5) | 20 (13.5) |
| 3+ | 31 (35.6) | 11 (7.4) |
Abbreviations: CD, Crohn’s disease; CKD, chronic kidney disease; IBD, inflammatory bowel disease; IQR, interquartile range.
Data are presented as count (percentage) unless otherwise specified.
| Variable . | CD with CKD (n = 87) . | CD without CKD (n = 148) . |
|---|---|---|
| Gender | ||
| Male | 49 (56.3) | 80 (54.1) |
| Female | 38 (43.7) | 68 (45.9) |
| Race | ||
| White | 79 (90.8) | 136 (91.9) |
| Black | 8 (9.2) | 12 (8.1) |
| Ethnicity | ||
| Hispanic | 26 (29.9) | 40 (27.0) |
| Non-Hispanic | 61 (70.1) | 108 (73.) |
| Age, mean (IQR) | 67 (18-91) | 66 (20-88) |
| Smoking status | ||
| Never smoker | 45 (51.7) | 79 (53.4) |
| Former smoker | 36 (41.4) | 57 (38.5) |
| Current smoker | 6 (6.9) | 12 (8.1) |
| Hypertension | 41 (47.1) | 40 (27.0) |
| Diabetes mellitus | 14 (16.1) | 15 (10.1) |
| Primary sclerosing cholangitis | 3 (3.4) | 2 (1.4) |
| End-stage renal disease | 13 (14.9) | 0 |
| History of kidney stones | 30 (34.5) | 8 (5.4) |
| History of transplant | 8 (9.2) | 0 |
| Kidney | 3 (3.4) | 0 |
| Liver | 4 (4.6) | 0 |
| Bowel | 1 (1.1) | 0 |
| Aminosalicylate use | ||
| Previous | 48 (55.2) | 105 (70.9) |
| Immunomodulator use | ||
| Current | 15 (17.2) | 39 (26.4) |
| Previous | 56 (64.4) | 79 (53.4) |
| Biologics use | ||
| Current | 47 (54.0) | 85 (57.4) |
| Previous | 61 (70.1) | 107 (72.3) |
| # of biologics used | ||
| 0 | 26 (29.9) | 41 (27.7) |
| 1 | 29 (33.3) | 56 (39.9) |
| 2 | 14 (16.1) | 25 (16.9) |
| 3+ | 18 (20.7) | 26 (17.5) |
| Steroid use | ||
| Previous | 80 (92.0) | 129 (87.2) |
| History of IBD-related surgery | 67 (77.0) | 74 (50.0) |
| # of IBD-related surgeries | ||
| 1 | 19 (21.8) | 43 (29.1) |
| 2 | 17 (19.5) | 20 (13.5) |
| 3+ | 31 (35.6) | 11 (7.4) |
| Variable . | CD with CKD (n = 87) . | CD without CKD (n = 148) . |
|---|---|---|
| Gender | ||
| Male | 49 (56.3) | 80 (54.1) |
| Female | 38 (43.7) | 68 (45.9) |
| Race | ||
| White | 79 (90.8) | 136 (91.9) |
| Black | 8 (9.2) | 12 (8.1) |
| Ethnicity | ||
| Hispanic | 26 (29.9) | 40 (27.0) |
| Non-Hispanic | 61 (70.1) | 108 (73.) |
| Age, mean (IQR) | 67 (18-91) | 66 (20-88) |
| Smoking status | ||
| Never smoker | 45 (51.7) | 79 (53.4) |
| Former smoker | 36 (41.4) | 57 (38.5) |
| Current smoker | 6 (6.9) | 12 (8.1) |
| Hypertension | 41 (47.1) | 40 (27.0) |
| Diabetes mellitus | 14 (16.1) | 15 (10.1) |
| Primary sclerosing cholangitis | 3 (3.4) | 2 (1.4) |
| End-stage renal disease | 13 (14.9) | 0 |
| History of kidney stones | 30 (34.5) | 8 (5.4) |
| History of transplant | 8 (9.2) | 0 |
| Kidney | 3 (3.4) | 0 |
| Liver | 4 (4.6) | 0 |
| Bowel | 1 (1.1) | 0 |
| Aminosalicylate use | ||
| Previous | 48 (55.2) | 105 (70.9) |
| Immunomodulator use | ||
| Current | 15 (17.2) | 39 (26.4) |
| Previous | 56 (64.4) | 79 (53.4) |
| Biologics use | ||
| Current | 47 (54.0) | 85 (57.4) |
| Previous | 61 (70.1) | 107 (72.3) |
| # of biologics used | ||
| 0 | 26 (29.9) | 41 (27.7) |
| 1 | 29 (33.3) | 56 (39.9) |
| 2 | 14 (16.1) | 25 (16.9) |
| 3+ | 18 (20.7) | 26 (17.5) |
| Steroid use | ||
| Previous | 80 (92.0) | 129 (87.2) |
| History of IBD-related surgery | 67 (77.0) | 74 (50.0) |
| # of IBD-related surgeries | ||
| 1 | 19 (21.8) | 43 (29.1) |
| 2 | 17 (19.5) | 20 (13.5) |
| 3+ | 31 (35.6) | 11 (7.4) |
Abbreviations: CD, Crohn’s disease; CKD, chronic kidney disease; IBD, inflammatory bowel disease; IQR, interquartile range.
Data are presented as count (percentage) unless otherwise specified.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
